The National Institute of Standards and Technology issued a request for information seeking ideas for improving the public’s return on investment from federally supported R&D. Here’s my submission.
WellDoc®, a leading digital health company, today announces hypertension and weight management solutions integrated within its digital therapeutic app for type 2 diabetes, BlueStar®. Later this year, WellDoc will launch its stand-alone product for individuals living with hypertension (high blood pressure) and stand-alone products are also in development for multiple chronic diseases.
The Washington area is rarely thought of as a hotbed for technology companies. The region’s biggest firms have generally gravitated toward the quiet, stable business of government contracting, while start-ups tend to move elsewhere in search of growth capital.
Teva Pharmaceutical Industries Ltd., the troubled Israeli manufacturer of generic drugs, will be moving its US headquarters from Pennsylvania to New Jersey, lured by 10-year, $40 million tax incentive plan.
Attending the Farm Progress Show at Boone, Iowa, this year? Add the Iowa AgriTech Accelerator to your list of exhibitors to visit.
When Viela Bio spun out of MedImmune in March, it started with six assets — three in clinical trials and three in preclinical development — putting it ahead of most startups and many spin-offs. “Other spin-offs often are developing assets that have been shelved for various reasons or that have been deprioritized,” Bing Yao, Ph.D., CEO, notes. “But for Viela Bio, this is a continuation of the programs, not a handoff.”
TEDCO, Maryland’s economic engine for technology companies, announced its recent investments through the Maryland Innovation Initiative (MII). With the latest round of funding, MII’s funding count for FY18 includes 38 technology assessment grants and seven start-up investments for a total of $5.56 million. True to its technology agnostic funding history, this year the startups ranged from medical devices to aeronautics and the sports industry.
The quest for innovation is a major driving force in pharma. From the discovery of therapeutic biologicals in the 1920s, such as Salvarsan and insulin, to the blockbuster drugs birthed in the 1990s, such as Lipitor and Humira, pharma has always been on a quest for novel, groundbreaking drug development.
Every entrepreneur has a “founder’s story” that serves to build the unique framework for why they are just the right person to solve a specific problem. For Aaron Chang, CEO of Renalert, that story began at Johns Hopkins University in the Masters of Bioengineering Innovation and Design program.
This seed round will send the startup into the next phase of its journey toward clinical trials.